Close Menu

LadaTech

This article has been updated with comments from Illumina.

In its suit, filed last August, LadaTech claimed that Illumina's Genome Analyzer and related products and services infringe a DNA amplification patent it holds.

LadaTech initially filed the suit in August, and said that Illumina refused to enter into a license agreement for the patent.

The suit claims that Illumina's Genome Analyzer and related products and services infringe a patent originally issued to Genelabs and now held by a firm called LadaTech.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.